Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
| ▸ | BAD | Q92934 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 3/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15654666 | 0.80 | KCNN4 (0.38) | KEAP1CES2CES1CA1CA2 | |
| SCHEMBL1601408 | 0.80 | CES2 (0.34) | BCL2L1BADCES2CES1CA1 | |
| SCHEMBL1205805 | 0.75 | NPC1 (0.42) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| SCHEMBL2780243 | 0.74 | TSHR (0.50) | BCL2L1BADCES2CES1CA1 | |
| SCHEMBL4957915 | 0.73 | TSHR (0.48) | BCL2L1BADCES2CES1CA1 | |
| SCHEMBL6633059 | 0.73 | MAPT (0.38) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL16267153 | 0.73 | ALDH1A1 (0.44) | CES2CES1KDM4EALDH1A1LMNA | |
| SCHEMBL865712 | 0.73 | TSHR (0.44) | CES2CES1CA1CA2ALDH1A1 | |
| SCHEMBL7000102 | 0.72 | SRD5A2 (0.46) | CES2CES1KDM4EALDH1A1HPGD | |
| SCHEMBL8418372 | 0.72 | TSHR (0.35) | CA1CA2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2022-05-19 | — | — | US | claimed |
| CN-112981482-B | Method for electroplating conductive material on semiconductor wafer | 无锡华友微电子有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3992184-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3992185-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | Shenzhen Cell Inspire Pharmaceutical Development Co., Ltd. (CN) | 2022-05-04 | — | — | EP | claimed |
| CN-113105411-A | Hydrazone amide derivatives and pharmaceutical compositions | 深圳市三启药物开发有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-112981482-A | Method for electroplating conductive material on semiconductor wafer | 无锡华友微电子有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-110330465-A | Hydrazone amide derivatives and its application in preparation prevention and treatment alopecia agent | 深圳市三启药物开发有限公司 | 2019-10-15 | — | — | CN | claimed |
| CN-110229118-A | Hydrazone amide derivatives and its preparing the application in osteosporosis resistant medicament | 深圳市三启药物开发有限公司 | 2019-09-13 | — | — | CN | claimed |
| CN-1394602-A | Benzoic acid substituted benzopyran fro curing atheroscleorsis | PFIZER (US) | 2003-02-05 | — | — | CN | claimed |
| US-5948813-A | Method of preventing allograft rejection | PFIZER INC. (US) | 1999-09-07 | — | — | US | claimed |
| CN-1041311-C | Benzopyran and related LTB4 antagonists | PFIZER (US) | 1998-12-23 | — | — | CN | claimed |
| JP-2765757-B2 | — | — | 1998-06-18 | — | — | JP | claimed |
| EP-0836850-A2 | Method of preventing allograft rejection | PFIZER INC. (US) | 1998-04-22 | — | — | EP | claimed |
| US-5684046-A | LEUKOTRIENE B4 ANTAGONIST AS ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS | PFIZER INC (US) | 1997-11-04 | — | — | US | claimed |
| EP-0623123-B1 | Benzopyran and related LTB4-antagonists | PFIZER (US) | 1997-04-23 | — | — | EP | claimed |
| US-5552435-A | ANTIINFLAMMATORY AGENTS, LEUKOTRIENE B4 ANTAGONISTS | PFIZER INC. (US) | 1996-09-03 | — | — | US | claimed |
| EP-0623123-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS. | PFIZER (US) | 1994-11-09 | — | — | EP | claimed |
| CN-1075318-A | Chromene and relevant leukotriene B 4Antagonist | PFIZER (US) | 1993-08-18 | — | — | CN | claimed |
| WO-1993015067-A1 | BENZOPYRAN AND RELATED LTB4 ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153688-A1 | HYDRAZONE AMIDE DERIVATIVES AND USE THEREOF IN PREPARATION OF ANTI-OSTEOPOROSIS DRUGS | SOST, HDAC5, PTH1R | BCL2L1 4299/4885BAD 1252/4885KEAP1 1271/4885 |
| US-20220153713-A1 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | FH, HDGF, HRH4 | BCL2L1 1380/4885BAD 162/4885KEAP1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.